<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316237</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-119-0101</org_study_id>
    <nct_id>NCT01316237</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the
      Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve
      Subjects with Chronic Hepatitis C Virus Infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with HCV RNA viral response as a measure of antiviral activity.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations and pharmacokinetic parameters of GS-6620 and its metabolites will be measured.</measure>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2) 50 mg GS-6620 or placebo QD in the morning with food [total daily dose (TDD) = 50 mg] for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
100 mg GS-6620 or placebo QD in the morning with food (TDD = 100 mg) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 3 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
300 mg GS 6620 or placebo QD in the morning with food (TDD = 300 mg) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 4 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
100 mg GS 6620 or placebo QD in the morning without food (TDD = 100 mg) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 5 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
300 mg GS 6620 or placebo QD in the morning without food (TDD = 300 mg) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 6 (N = 10, genotype 2 or genotype 3): (Active drug: 8, Matching Placebo: 2)
900 mg GS 6620 or placebo QD in the morning without food (TDD = 900 mg) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 7 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
450 mg GS 6620 or placebo, administered BID with food (TDD = 900 mg) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 9 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
900 mg GS 6620 or placebo BID in the with food (TDD = 1800 mg) for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cohort 11 (N = 10, genotype 1 : (Active drug: 8, Matching Placebo: 2)
Up to 450 mg GS-6620 or placebo as an oral solution, BID, 12 hours apart in the fasted state, 2 hours after a meal (up to TDD = up to 900 mg) for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620</intervention_name>
    <description>GS-6620 tablet, 50 mg QD</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620</intervention_name>
    <description>GS-6620 tablet, 100 mg QD</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620</intervention_name>
    <description>GS-6620 tablet, 300 mg QD</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620</intervention_name>
    <description>GS-6620 tablet, 100 mg QD, Fasted</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620</intervention_name>
    <description>GS-6620 tablet, 300 mg QD, Fasted</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620</intervention_name>
    <description>GS-6620 tablet, 900 mg QD, Fasted</description>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620 tablet, 450 mg BID</intervention_name>
    <description>GS-6620 tablet, 450 mg BID</description>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620 tablet</intervention_name>
    <description>GS-6620 tablet, 900mg , BID</description>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6620 tablet</intervention_name>
    <description>GS-6620 tablet, 900 mg</description>
    <arm_group_label>Cohort 11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (18-60 years of age or up to 64 years of age with approval)

          -  Documented chronic HCV infection to be of at least 6 months duration and plasma HCV
             RNA ≥ 5 log10 IU/mL at screening.

          -  HCV treatment naïve

          -  Estimated creatinine clearance ≥ 80 mL/min,

          -  QTcF interval ≤ 450 msec, QRS duration &lt; 100 msec, PR interval &lt; 220 msec,

          -  Body mass index (BMI) of 19.0 to 34.0 kg/m2, inclusive.

          -  Eligible subjects must also be HCV treatment-naïve.

        Exclusion Criteria:

          -  Subjects with prior documentation of cirrhosis, excessive current alcohol intake, any
             evidence of hepatocellular carcinoma (i.e., α-fetoprotein &gt; 50 ng/mL or by any other
             standard of care measure)

          -  Urine drug screen positive for illicit/illegal drugs

          -  ALT and AST levels &gt; 5 times the upper limit of the normal range (ULN)

          -  Direct bilirubin &gt; ULN, clinical or other laboratory evidence of hepatic
             decompensation (i.e., platelets &lt; 100,000/mm3, prothrombin time ≥ 1.5 × ULN and
             albumin &lt; 3.5 g/dL) are not eligible for study participation.

          -  Subjects with an absolute neutrophil count (ANC) &lt; 1,000 cells/mm3 (&lt; 750 cells/mm3
             for black or African-American subjects), hemoglobin (Hb) &lt; 11 g/dL,

          -  Coinfected with hepatitis B virus (HBV), human immunodeficiency virus (HIV), or
             another HCV genotype (other than type 1 for Cohorts 1-5 and type 2 or 3 for Cohort 6)
             are not eligible for study participation.

          -  Evidence of hepatocellular carcinoma

          -  Any sign of decompensated liver disease, including prothrombin time ≥ 1.5 X ULN,
             platelets &lt; 100,000/mm3 or albumin &lt; 3.5 g/dL at screening OR current or prior history
             of clinical hepatic decompensation (e.g., ascites, jaundice, encephalopathy or
             variceal hemorrhage)

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol

          -  History of a primary gastrointestinal disorder that could interfere with the
             absorption of the study drug or that could interfere with normal gastrointestinal
             anatomy or motility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Rossi, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research, LC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles River Clinical Services Northwest</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion De Investigacion De Diego</name>
      <address>
        <city>Puerto Rico</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <last_update_submitted>March 22, 2012</last_update_submitted>
  <last_update_submitted_qc>March 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>HCV RNA</keyword>
  <keyword>Polymerase inhibitor</keyword>
  <keyword>Treatment naïve</keyword>
  <keyword>GS-6620</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

